| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer |
2012-000526-21: Vaccination och immunologiskt minne hos nyligen stamcells-transplanterade patienter med multipelt myelom |
|
|
| Ongoing | 4 | 50 | Europe | Suspension for injection, Prevenar 13, Injektionsvätska, suspension, Pneumovax® Injektionsvätska, lösning | Västra Götalandregionen (VGR), Västra Götalandregionen, Västra Götalandsregionen, Västra Götalandregionen | Multipelt myelom (MM) är en elakartad blodsjukdom som orsakas av ohämmad tillväxt av immunförsvarsceller. Patienter med MM löper ökad risk att insjukna i allvarliga infektioner ofta orsakade av pneumokocker på grund av defekt immunförsvar. Risken ökar ytterligare i anslutning till benmärgs-transplantationer., Patienter med multipelt myelom (MM), en elakartad blodsjukdom, löper stor risk att insjukna i allvarliga infektioner i samband med benmärgstransplantation., Diseases [C] - Immune System Diseases [C20] | | | | |
2014-004799-50: Regulatory role of the immune system of Prevenar 13 vaccine in children with asthma and diabetes. Papel regulador del sistema inmune de la vacuna Prevenar 13 en niños con asma y diabetes . |
|
|
| Ongoing | 4 | 150 | Europe | Prevenar 13, Suspension for injection, Prevenar 13 | Federico Martinon Torres, Genetic, Vaccines, Infectious Disease and Pediatrics Research Group | Allergic asthma and type 1 diabetes mellitus in pediatric subjects. Asma alérgica y diabetes mellitus tipo 1 en sujetos pediátricos., Asthma and diabetes in children Asma y diabetes en niños, Diseases [C] - Immune System Diseases [C20] | | | | |
2015-000817-32: Assessing responses to the booster dose of pneumococcal vaccine in children who had less than the standard number of doses as babies, as well as meningococcal B vaccine as babies. |
|
|
| Ongoing | 4 | 200 | Europe | Bexsero, Prevenar13, Infanrix-IPV, Menitorix, Injection, Bexsero, Prevenar13, Infanrix-IPV, Menitorix | University of Oxford, Department of Health (UK) | Immunological responses to vaccination in health y participants under reduced dose vaccine schedules, how well babies respond to different vaccine schedules, Body processes [G] - Immune system processes [G12] | | | | |
| Ongoing | 4 | 200 | Europe | PEDIACEL, Meningitec, Menitorix, Pediacel, Prevenar 13, Meningitec, Menitorix, Pediacel, Prevenar 13, Meningitec, Menitorix | St George\'s University of London, St George's University of London | These are vaccines routinely given to infants in the UK and are not administered with respect to existing medical condition(s), rather in the prevention of diseases. | | | | |
2009-016579-31: An open label randomised controlled study to evaluate the induction of immune memory following infant vaccination with a glyco-conjugate Neisseria meningitidis serogroup C vaccine and to assess the immunological impact of administering routine infant immunisations in consistent versus alternating limbs |
|
|
| Ongoing | 4 | 468 | Europe | Menjugate Kit, Pediacel, Menitorix, Prevenar 13, NeisVac-C, Menjugate Kit, Pediacel, Menitorix, Prevenar 13, NeisVac-C | University of Oxford | Active immunisation of children for the prevention of invasive diseases caused by Neisseria meningitidis serogroup C, Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. | | | | |
2009-017498-39: A follow-on, multi-centre, open-label, clinical, phase 3 trial to investigate the persistence of serotype-specific antibodies at 40 months of age in children who have received either the 7-valent or the 13-valent pneumococcal conjugate vaccine at 2, 4 and 12 months of age and assessing the immunogenicity of a 13-valent pneumococcal conjugate vaccine booster dose given at 40 months of age |
|
|
| Ongoing | 4 | 100 | Europe | Prevenar 13, Prevenar 13 | University of Oxford | Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks to 5 years of age. | | | | |
2012-003484-22: Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly |
|
|
| Ongoing | 4 | 500 | Europe | Prevenar13, Havrix, Epaxal, Prevenar13, Havrix, Epaxal, Prevenar13, Havrix, Epaxal | Helsinki University Central Hospital | 18 years old or older volunteers with general good health | | | | |
2012-003026-25: Study to evaluate the immune response of infants to a new infant immunisation schedule which includes a new vaccine protecting against hepatitis B and a reduced dose schedule for meningococcal group C conjugate vaccine. |
|
|
| Ongoing | 4 | 300 | Europe | Infanrix Hexa, Prevenar 13, Menjugate, Menitorix, NeisVac-C, Priorix, M-M-RVAXPRO, Rotarix, Infanrix Hexa, Prevenar13, Menjugate, Menitorix, NeisVac-C, Priorix, M-M-RVAXPRO, Rotarix, Infanrix Hexa, Prevenar13, Menjugate, Menitorix, NeisVac-C, Priorix, M-M-RVAXPRO, Rotarix | Health Protection Agency, Department of Health | Not applicable | | | | |
| Ongoing | 4 | 110 | Europe | Prevenar 13, AVAXIM, EU/1/09/590/001, Prevenar 13, AVAXIM, Prevenar 13, AVAXIM | Royal Liverpool University Hospital, Liverpool School of Tropical Medicine | Pneumococcal disease | | | | |
2014-000260-17: Pneumococcal conjugate vaccines in the elderly: The role of carrier-specific T cells Konjugierte Pneumokokken-Impfstoffe im Alter: Einfluss von Trägerprotein-spezifischen T-Zellen |
|
|
| Ongoing | 4 | 150 | Europe | Prevenar-13, Boostrix, Prevenar-13, Boostrix, Prevenar-13, Boostrix | Universität Innsbruck, Institut für Biomedizinische Alternsforschung, University of Innsbruck, Austrian National Bank, Anniversery Fund | This study investigates humoral immune responses to pneumococcal conjugate vaccine as well as humoral and T cell responses to the diphtheria-component of the Tdap vaccine. Healthy adults over 50 years of age will receive both vaccines sequentially or simulaneously. Both vaccines are licensed for this age group | | | | |
2012-005713-39: Reponse to vaccination in patients with bonemarrowcancer who are treated with chemotherapy. Respons op vaccinatie bij patienten met beenmergkanker die behandeld worden met chemotherapie. |
|
|
| Ongoing | 4 | 140 | Europe | Prevnar 13, Influvac or Vaxigrip, RVG 25853, Prevnar 13, Influenza vaccine (Influvac or Vaxigrip), Prevnar 13, Influenza vaccine (Influvac or Vaxigrip) | St. Antonius Hospital, St. Antonius Hospital | multiple myeloma multipel myeloom | | | | |
| Ongoing | 4 | 120 | Europe | Prevenar-13, N/A, Prevenar-13, Prevenar-13 | University Hospital Southampton NHS Foundation Trust, NIHR | Childhood Acute Lymphoblastic Leukaemia | | | | |
| Not yet recruiting | 4 | 214 | Europe | Prevenar 13, Solution for injection, Prevenar 13 | Guy's and St Thomas' NHS Foundation Trust, NIHR Clinician Scientist Award | Sepsis, Sepsis, Body processes [G] - Immune system processes [G12] | | | | |
| Not yet recruiting | 4 | 240 | Europe | INFANRIX-HEXA, Vaxelis (DTaP -HB-IPV-Hib), Bexsero, Prevenar 13, Menitorix, Rotarix, M-M-RVAXPRO, Priorix, Suspension for injection, Powder and solvent for solution for injection, Oral suspension, Powder and solvent for suspension for injection, , INFANRIX-HEXA, Vaxelis (DTaP -HB-IPV-Hib), Bexsero, Prevenar 13, Menitorix, Rotarix, M-M-RVAXPRO, Priorix | Clinical Trials and Research Governance (CTRG) | Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy., Compare the immunogenicity of the Haemophilus influenza type B (Hib) component of 6in1-IH (Infanrix-Hexa) and 6in1-V (Vaxelis) when co-administered with 4CMenB in the UK routine immunisation schedule., Body processes [G] - Immune system processes [G12] | | | | |
2019-000836-24: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults. Afweerreacties tegen influenza en pneumokokken vaccin vergeleken tussen 3 leeftijdsgroepen |
|
|
| Not yet recruiting | 4 | 385 | Europe | EU/1/09/590, Suspension for injection in pre-filled syringe, Dispersion for injection, Prevenar-13 | National Institute of Health and the Environment, Innovative Medicines Initiative | Healthy volunteers above 25 years of age, Healthy volunteers above 25 years of age, Body processes [G] - Immune system processes [G12] | | | | |
2020-000863-22: Safety and immune respons following meningococcal and pneumococcal vaccination among adult people living with HIV. |
|
|
| Not yet recruiting | 4 | 55 | Europe | Prevenar-13, Pneumovax, Menveo, Bexsero | Thomas Benfield, Hvidovre Hospital, Department of Infectious Diseases | Immunogenicity following pneumococcal and meningococcal vaccination among people living with HIV, Immune response following pneumococcal and meningococcal vaccination among people living with HIV, Body processes [G] - Immune system processes [G12] | | | | |
2019-002585-12: Study to Assess the Immune Response and the Safety Profile of DTaP-IPVHB- PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian Infants Studio per valutare la risposta immunitaria e il profilo di sicurezza del vaccino combinato DTaP-IPVHB- PRP ~ T somministrato in concomitanza o in sequenza con il vaccino 4CMenB in infanti italiani |
|
|
| Ongoing | 4 | 396 | Europe | NA, [NA], Suspension for injection, Suspension for injection in pre-filled syringe, Hexyon sospensione iniettabile - vaccino coniugato (adsorbito) contro difterite, tetano, pertosse (componente acellulare), epatite B (rDNA), poliomielite (inattivato) ed Haemophilus influenzae di tipo b, Bexsero sospensione iniettabile in siringa preriempita - Vaccino contro il meningococco di gruppo B (rDNA, componente, adsorbito), Prevenar 13 sospensione iniettabile - Vaccino pneumococcico polisaccaridico coniugato (13 valente adsorbito) | SANOFI PASTEUR, Sanofi Pasteur, Sanofi Pasteur | Haemophilus influenzae type b immunisation Immunizzazione Haemophilus influenzae di tipo B, Active immunization against diphtheriae, tetanus, pertussis, hepatitis B, poliomyelitis & invasive infections caused by Haemophilus influenzae type b Immunizzazione attiva contro difterite, tetano, pertosse, epatite B, poliomielite e infezioni invasive causate da Haemophilus influenzae di tipo b, Diseases [C] - Virus Diseases [C02] | | | | |
NCT05316831: Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia |
|
|
| Completed | 4 | 77 | Europe | PCV13, Prevenar13, PPSV23, Pneumovax23 | Region Örebro County | CLL, Vaccine Response | 06/21 | 10/22 | | |
FPCV, NCT03489018: The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants |
|
|
| Active, not recruiting | 4 | 2100 | RoW | PCV10, Synflorix (GlaxoSmithKline plc.), 10-valent pneumococcal conjugate vaccine, PCV13, Prevnar 13 (Pfizer Inc.), 13-valent pneumococcal conjugate vaccine, Prevnar13 | London School of Hygiene and Tropical Medicine, University College, London, KEMRI-Wellcome Trust Collaborative Research Program, Bill and Melinda Gates Foundation, National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU), Wellcome Trust | Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against | 09/22 | 12/24 | | |
| Completed | 4 | 123 | Europe | PCV13, Prevenar 13, PPV23, Pneumovax (MSD) | Jena University Hospital | Pneumococcal Infections | 11/22 | 11/23 | | |
NCT04978038: Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs |
|
|
| Not yet recruiting | 4 | 414 | Canada | mRNA- COVID-19, Pfizer-BioNtech mRNA- COVID-19, Prevnar13, Pneumococcal Vaccine | Mark Loeb | SARS-CoV2 Infection, Coronavirus Infection | 11/22 | 12/22 | | |
| Completed | 4 | 214 | Europe | Prevenar 13, Sodium Chloride 0.9% | Guy's and St Thomas' NHS Foundation Trust, National Institute for Health Research, United Kingdom | Sepsis | 08/23 | 08/23 | | |
| Recruiting | 4 | 516 | Europe | PPV23, pneumovax, PCV13, prevenar, Saline for injection | Liverpool School of Tropical Medicine, Pfizer | Streptococcus Pneumonia | 07/23 | 12/23 | | |
NCT04080531: Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders |
|
|
| Completed | 4 | 165 | US | Pneumococcal 13-valent Conjugate Vaccine, PCV13, Prevnar 13, Trivalent Influenza Vaccine, Flu shot, Flu vaccination, Fluzone, Fluzone HD, Fluzone High-dose, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV | Emory University, Sanofi, National Institutes of Health (NIH), National Cancer Institute (NCI) | Plasma Cell Neoplasm | 05/21 | 12/22 | | |
NCT03729778: Impact of HIV-1 and Aging on Mucosal Vaccine Responses |
|
|
| Recruiting | 4 | 100 | US | Prevnar-13 | VA Eastern Colorado Health Care System | HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections | 01/24 | 01/25 | | |
NCT05170399: Vaccine Responses in Patients With B Cell Malignancies |
|
|
| Recruiting | 4 | 500 | US | Fluzone, Shingrix, Flucelvax, Afluria, PREVNAR 13, Heplisav -B, Pfizer-COVID-19 Vaccine, FluLaval, Fluarix, PNEUMOVAX 23, PREVNAR 20, AREXVY, ABRYSVO | National Heart, Lung, and Blood Institute (NHLBI) | Lymphoma | 08/24 | 08/24 | | |
| Recruiting | 4 | 160 | Europe | Prevenar13 Pneumo-23 | Poitiers University Hospital | Vaccine, Streptococcus Pneumoniae, Acute Myeloid Leukemia, Lymphoma, Non-Hodgkin | 06/26 | 06/26 | | |
MENPI, NCT04875819: Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV |
|
|
| Recruiting | 4 | 55 | Europe | Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, Menveo® and Bexsero®, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine, Prevenar13® and Pneumovax23® | Thomas Benfield | Hiv, Meningococcal Infections, Pneumococcal Infections | 12/26 | 12/26 | | |
2012-002657-30: Comparing the effectivity of two different pneumococcal vaccines against severe pneumococcal diseases in adult kidney and liver transplant patients |
|
|
| Ongoing | 3/4 | 150 | Europe | Pneumovax, Prevenar 13, Pneumovax, Prevenar 13, Pneumovax | HYKS-instituutti, HYKS instituutti | Immunogenicity of pneumococcal vaccines in liver and kidney transplant patients | | | | |
